- Home
- APM vs GLMD Comparison
APM vs GLMD Comparison
Compare APM & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- GLMD
- Stock Information
- Founded
- APM 2010
- GLMD 2000
- Country
- APM United Kingdom
- GLMD Israel
- Employees
- APM N/A
- GLMD N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- GLMD Health Care
- Exchange
- APM Nasdaq
- GLMD Nasdaq
- Market Cap
- APM 4.1M
- GLMD 4.6M
- IPO Year
- APM 2018
- GLMD 2014
- Fundamental
- Price
- APM $1.15
- GLMD $2.90
- Analyst Decision
- APM
- GLMD
- Analyst Count
- APM 0
- GLMD 0
- Target Price
- APM N/A
- GLMD N/A
- AVG Volume (30 Days)
- APM 7.0M
- GLMD 41.9K
- Earning Date
- APM 12-20-2024
- GLMD 11-14-2024
- Dividend Yield
- APM N/A
- GLMD N/A
- EPS Growth
- APM N/A
- GLMD N/A
- EPS
- APM 0.00
- GLMD N/A
- Revenue
- APM N/A
- GLMD N/A
- Revenue This Year
- APM $157,729.10
- GLMD N/A
- Revenue Next Year
- APM N/A
- GLMD N/A
- P/E Ratio
- APM $345.64
- GLMD N/A
- Revenue Growth
- APM N/A
- GLMD N/A
- 52 Week Low
- APM $0.46
- GLMD $2.56
- 52 Week High
- APM $17.49
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- APM 47.12
- GLMD 45.51
- Support Level
- APM $1.21
- GLMD $2.84
- Resistance Level
- APM $1.30
- GLMD $3.01
- Average True Range (ATR)
- APM 0.75
- GLMD 0.22
- MACD
- APM -0.06
- GLMD -0.02
- Stochastic Oscillator
- APM 4.58
- GLMD 13.41
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.